

References

I-5043

1. Prostate Cancer. American Cancer Society. Accessed August 9, 2022. <https://www.cancer.org/cancer/prostate-cancer.html>
2. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. Mar 1966; 50(3): 125-8. PMID 5948714
3. SEER Database. Accessed August 8, 2022. <https://seer.cancer.gov/seerinqury/index.php?page=view&id=20170036&type=q>
4. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. Sep 16 2021; 385(12): 1091-1103. PMID 34161051
5. Pluvicto [package insert]. Advanced Accelerator Applications USA, Inc; 2022.
6. Locametz [package insert]. Advanced Accelerator Applications USA, Inc; 2022.
7. Pylarify [package insert]. Progenics Pharmaceuticals, Inc.; 2022.
8. Illuccix [package insert]. Telix Pharmaceuticals US, Inc.; 2022.
9. Sadaghiani MS, Sheikhabaei S, Werner RA, et al. 177 Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis. Prostate. May 2022; 82(7): 826-835. PMID 35286735
10. Hofman MS, Emmett L, Sandhu S, et al. [177 Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. Feb 27 2021; 397(10276): 797-804. PMID 33581798
11. Calais J, Gafita A, Eiber M, et al. Prospective phase 2 trial of PSMA-targeted molecular Radiotherapy with 177 Lu-PSMA-617 for metastatic castration-resistant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. J Nucl Med. Oct 2021; 62(10): 1440-1446. PMID 34016732
12. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Prostate Cancer, version 4.2022. NCCN. Accessed August 9, 2022. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf